p53 deficiency provokes urothelial proliferation and synergizes with activated Ha-ras in promoting urothelial tumorigenesis

Jing Gao, Hong Ying Huang, Joanne Pak, Jin Cheng, Zhong Ting Zhang, Ellen Shapiro, Angel Pellicer, Tung Tien Sun, Xue Ru Wu

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Mutation and deletion of the p53 tumor suppressor gene are arguably the most prevalent among the multiple genetic alterations found in human bladder cancer, but these p53 defects are primarily associated with the advanced diseases, and their roles in bladder tumor initiation and in synergizing with oncogenes in tumor progression have yet to be defined. Using the mouse uroplakin II gene promoter, we have targeted into urothelium of transgenic mice a dominant-negative mutant of p53 that lacks the DNA-binding domain but retains the tetramerization domain. Urothelium-expressed p53 mutant binds to and stabilizes the endogenous wild-type p53, induces nuclear abnormality, hyperplasia and occasionally dysplasia, without eliciting frank carcinomas. Concurrent expression of the p53 mutant with an activated Ha-ras, the latter of which alone induces urothelial hyperplasia, fails to accelerate tumor formation. In contrast, the expression of the activated Ha-ras in the absence of p53, as accomplished by crossing the activated Ha-ras transgenic mice with the p53 knockout mice, results in early-onset bladder tumors that are either low-grade superficial papillary or high grade in nature. These results provide the first in vivo experimental evidence that p53 deficiency predisposes the urothelium to hyperproliferation, but is insufficient for bladder tumorigenesis; that the mere reduction of p53 dosage, as produced in transgenic mice expressing the dominant-negative p53 or in heterozygous p53 knockouts, is incapable of synergizing with Ha-ras to induce bladder tumors; and that the complete loss of p53 is a prerequisite for collaborating with activated Ha-ras to promote bladder tumorigenesis.

Original languageEnglish (US)
Pages (from-to)687-696
Number of pages10
JournalOncogene
Volume23
Issue number3
DOIs
StatePublished - Jan 22 2004
Externally publishedYes

Fingerprint

Urinary Bladder Neoplasms
Urothelium
Carcinogenesis
Transgenic Mice
Hyperplasia
Urinary Bladder
Sequence Deletion
Tumor Suppressor Genes
Oncogenes
Knockout Mice
Neoplasms
Carcinoma
DNA
Genes

Keywords

  • Bladder cancer
  • Oncogene
  • p53
  • Ras
  • Suppressor gene
  • Tumor

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics

Cite this

p53 deficiency provokes urothelial proliferation and synergizes with activated Ha-ras in promoting urothelial tumorigenesis. / Gao, Jing; Huang, Hong Ying; Pak, Joanne; Cheng, Jin; Zhang, Zhong Ting; Shapiro, Ellen; Pellicer, Angel; Sun, Tung Tien; Wu, Xue Ru.

In: Oncogene, Vol. 23, No. 3, 22.01.2004, p. 687-696.

Research output: Contribution to journalArticle

Gao, J, Huang, HY, Pak, J, Cheng, J, Zhang, ZT, Shapiro, E, Pellicer, A, Sun, TT & Wu, XR 2004, 'p53 deficiency provokes urothelial proliferation and synergizes with activated Ha-ras in promoting urothelial tumorigenesis', Oncogene, vol. 23, no. 3, pp. 687-696. https://doi.org/10.1038/sj.onc.1207169
Gao, Jing ; Huang, Hong Ying ; Pak, Joanne ; Cheng, Jin ; Zhang, Zhong Ting ; Shapiro, Ellen ; Pellicer, Angel ; Sun, Tung Tien ; Wu, Xue Ru. / p53 deficiency provokes urothelial proliferation and synergizes with activated Ha-ras in promoting urothelial tumorigenesis. In: Oncogene. 2004 ; Vol. 23, No. 3. pp. 687-696.
@article{70d56a8e9ad440039402268b3e27384f,
title = "p53 deficiency provokes urothelial proliferation and synergizes with activated Ha-ras in promoting urothelial tumorigenesis",
abstract = "Mutation and deletion of the p53 tumor suppressor gene are arguably the most prevalent among the multiple genetic alterations found in human bladder cancer, but these p53 defects are primarily associated with the advanced diseases, and their roles in bladder tumor initiation and in synergizing with oncogenes in tumor progression have yet to be defined. Using the mouse uroplakin II gene promoter, we have targeted into urothelium of transgenic mice a dominant-negative mutant of p53 that lacks the DNA-binding domain but retains the tetramerization domain. Urothelium-expressed p53 mutant binds to and stabilizes the endogenous wild-type p53, induces nuclear abnormality, hyperplasia and occasionally dysplasia, without eliciting frank carcinomas. Concurrent expression of the p53 mutant with an activated Ha-ras, the latter of which alone induces urothelial hyperplasia, fails to accelerate tumor formation. In contrast, the expression of the activated Ha-ras in the absence of p53, as accomplished by crossing the activated Ha-ras transgenic mice with the p53 knockout mice, results in early-onset bladder tumors that are either low-grade superficial papillary or high grade in nature. These results provide the first in vivo experimental evidence that p53 deficiency predisposes the urothelium to hyperproliferation, but is insufficient for bladder tumorigenesis; that the mere reduction of p53 dosage, as produced in transgenic mice expressing the dominant-negative p53 or in heterozygous p53 knockouts, is incapable of synergizing with Ha-ras to induce bladder tumors; and that the complete loss of p53 is a prerequisite for collaborating with activated Ha-ras to promote bladder tumorigenesis.",
keywords = "Bladder cancer, Oncogene, p53, Ras, Suppressor gene, Tumor",
author = "Jing Gao and Huang, {Hong Ying} and Joanne Pak and Jin Cheng and Zhang, {Zhong Ting} and Ellen Shapiro and Angel Pellicer and Sun, {Tung Tien} and Wu, {Xue Ru}",
year = "2004",
month = "1",
day = "22",
doi = "10.1038/sj.onc.1207169",
language = "English (US)",
volume = "23",
pages = "687--696",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - p53 deficiency provokes urothelial proliferation and synergizes with activated Ha-ras in promoting urothelial tumorigenesis

AU - Gao, Jing

AU - Huang, Hong Ying

AU - Pak, Joanne

AU - Cheng, Jin

AU - Zhang, Zhong Ting

AU - Shapiro, Ellen

AU - Pellicer, Angel

AU - Sun, Tung Tien

AU - Wu, Xue Ru

PY - 2004/1/22

Y1 - 2004/1/22

N2 - Mutation and deletion of the p53 tumor suppressor gene are arguably the most prevalent among the multiple genetic alterations found in human bladder cancer, but these p53 defects are primarily associated with the advanced diseases, and their roles in bladder tumor initiation and in synergizing with oncogenes in tumor progression have yet to be defined. Using the mouse uroplakin II gene promoter, we have targeted into urothelium of transgenic mice a dominant-negative mutant of p53 that lacks the DNA-binding domain but retains the tetramerization domain. Urothelium-expressed p53 mutant binds to and stabilizes the endogenous wild-type p53, induces nuclear abnormality, hyperplasia and occasionally dysplasia, without eliciting frank carcinomas. Concurrent expression of the p53 mutant with an activated Ha-ras, the latter of which alone induces urothelial hyperplasia, fails to accelerate tumor formation. In contrast, the expression of the activated Ha-ras in the absence of p53, as accomplished by crossing the activated Ha-ras transgenic mice with the p53 knockout mice, results in early-onset bladder tumors that are either low-grade superficial papillary or high grade in nature. These results provide the first in vivo experimental evidence that p53 deficiency predisposes the urothelium to hyperproliferation, but is insufficient for bladder tumorigenesis; that the mere reduction of p53 dosage, as produced in transgenic mice expressing the dominant-negative p53 or in heterozygous p53 knockouts, is incapable of synergizing with Ha-ras to induce bladder tumors; and that the complete loss of p53 is a prerequisite for collaborating with activated Ha-ras to promote bladder tumorigenesis.

AB - Mutation and deletion of the p53 tumor suppressor gene are arguably the most prevalent among the multiple genetic alterations found in human bladder cancer, but these p53 defects are primarily associated with the advanced diseases, and their roles in bladder tumor initiation and in synergizing with oncogenes in tumor progression have yet to be defined. Using the mouse uroplakin II gene promoter, we have targeted into urothelium of transgenic mice a dominant-negative mutant of p53 that lacks the DNA-binding domain but retains the tetramerization domain. Urothelium-expressed p53 mutant binds to and stabilizes the endogenous wild-type p53, induces nuclear abnormality, hyperplasia and occasionally dysplasia, without eliciting frank carcinomas. Concurrent expression of the p53 mutant with an activated Ha-ras, the latter of which alone induces urothelial hyperplasia, fails to accelerate tumor formation. In contrast, the expression of the activated Ha-ras in the absence of p53, as accomplished by crossing the activated Ha-ras transgenic mice with the p53 knockout mice, results in early-onset bladder tumors that are either low-grade superficial papillary or high grade in nature. These results provide the first in vivo experimental evidence that p53 deficiency predisposes the urothelium to hyperproliferation, but is insufficient for bladder tumorigenesis; that the mere reduction of p53 dosage, as produced in transgenic mice expressing the dominant-negative p53 or in heterozygous p53 knockouts, is incapable of synergizing with Ha-ras to induce bladder tumors; and that the complete loss of p53 is a prerequisite for collaborating with activated Ha-ras to promote bladder tumorigenesis.

KW - Bladder cancer

KW - Oncogene

KW - p53

KW - Ras

KW - Suppressor gene

KW - Tumor

UR - http://www.scopus.com/inward/record.url?scp=1242318513&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1242318513&partnerID=8YFLogxK

U2 - 10.1038/sj.onc.1207169

DO - 10.1038/sj.onc.1207169

M3 - Article

C2 - 14737103

AN - SCOPUS:1242318513

VL - 23

SP - 687

EP - 696

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 3

ER -